[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346399-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346399-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","synergistic-effects-of-anticoagulants-and-platelet-aggregation-inhibitors-with-immune-checkpoint-inhibitors-in-cancer-therapy-a-comprehensive-review-of-preclinical-and-clinical-evidence","Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy - a comprehensive review of preclinical and clinical evidence","","Cancer therapy is undergoing rapid development, driving interest in whether anticoagulation can synergize with immune checkpoint inhibitor (ICI) treatment. Anticoagulants may exert immunomodulatory effects that reshape the tumor microenvironment, promote immune-cell infiltration, strengthen antitumor immunity, and potentially limit metastasis. This systematic review synthesizes preclinical and clinical evidence on mechanisms and outcomes, concluding that results support continued investigation of combined strategies, especially involving Factor Xa and antiplatelet agents.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/synergistic-effects-of-anticoagulants-and-platelet-aggregation-inhibitors-with-immune-checkpoint-inhibitors-in-cancer-therapy-a-comprehensive-review-of-preclinical-and-clinical-evidence/346399/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/synergistic-effects-of-anticoagulants-and-platelet-aggregation-inhibitors-with-immune-checkpoint-inhibitors-in-cancer-therapy-a-comprehensive-review-of-preclinical-and-clinical-evidence/346399.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this comprehensive review?","Question",{"text":63,"@type":64},"The review evaluates synergistic effects between anticoagulants and platelet aggregation inhibitors when combined with immune checkpoint inhibitors in cancer therapy, based on both preclinical and clinical evidence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What do preclinical studies suggest about combining ICIs with anticoagulants?",{"text":68,"@type":64},"Preclinical studies consistently indicate improved antitumor activity, including inhibition of tumor growth and metastasis, with agents such as low molecular weight heparin and oral Factor Xa inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"How do clinical findings compare, and what future research is recommended?",{"text":72,"@type":64},"Clinical results are mixed, though some retrospective evidence suggests potential benefit with Factor Xa inhibitors and antiplatelet agents; the study recommends prospective randomized trials to clarify interactions and outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346399,1791244257,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Open access Original research  \n Synergistic effects of anticoagulants and  \nplatelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence  \nJulian Kött  ,1,2 Nina Matthes,1,2 Alexander T Bauer,1,2 Noah Zimmermann,1,2 Tim Zell,1,2 Daniel J Smit  ,2,3 Stefan W Schneider,1,2 Christoffer Gebhardt  1,2  \nTo cite: Kött J, Matthes N, Bauer AT, et al. Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy:  \na comprehensive review of preclinical and clinical evidence. Journal for ImmunoTherapy of Cancer 2026;14:e013879 . doi:10.1136/jitc-2025-013879  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013879](jitc-2025-013879)) .  \nJK and NM are joint first authors.  \nSWS and CG are joint senior authors.  \nAccepted 16 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Julian Kött; [j.koett@uke.de](j.koett@uke.de)  \nABSTRACT  \nBackground The rapidly advancing field of cancer therapy has sparked growing interest in the potential synergy between anticoagulation and immune checkpoint inhibitor (ICI) therapy. Recent research highlights that anticoagulants, traditionally used forthromboprophylaxis and managing thromboembolicevents, may also exhibit immunomodulatory properties. These properties can influence the  \ntumor microenvironment by promoting immune cell infiltration, enhancing antitumor immune responses, and potentially reducing metastasis. This emerging evidence underscores the complex interplay between coagulation pathways and immune regulation, paving the way for further exploration of the clinical benefits of combining anticoagulation with ICI therapy.  \nMethods A systematic review was conducted to synthesize the current evidence on the interplay between anticoagulation and ICI. Relevant studies examining their mechanisms of action, clinical outcomes, and potential interactions were identified and analyzed. Comprehensive database searches were performed to ensure a thorough and inclusive review of the literature.  \nResults Preclinical studies consistently show that combining ICIs with anticoagulants can enhance cancer treatment by inhibiting tumor growth and metastasis. In particular, low molecular weight heparin, oral factor Xa (FXa) inhibitors, and platelet inhibitors have demonstrated synergistic effects with ICI. However, these findings have not been consistently replicated in clinical settings. While two retrospective studies reported no significant impact of anticoagulants on ICI efficacy, one retrospective study found improved outcomes in advanced melanoma patients treated with ICI and FXa inhibitors. Additionally, another retrospective study revealed a significant association between platelet aggregation inhibition and extended progression-free survival.  \nConclusions Our literature review underscores the intricate relationship between anticoagulation and  \nICIs in cancer therapy. Future studies should prioritize exploring the interactions between ICI, FXa inhibitors, and antiplatelet agents.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Recent research indicates that anticoagulants, beyond their traditional role in thromboprophylaxis, also exhibit immunomodulatory effects that may influence the tumor microenvironment and enhance the activity of immune checkpoint inhibitors (ICIs) .\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This systematic review shows that preclinical studies consistently demonstrate synergistic antitumor effects between anticoagulation and ICI, while clinical findings are mixed but suggest potential benefit particularly with Factor X","cbCaieEV51Iqv2OR","https://ap.wps.com/l/cbCaieEV51Iqv2OR","pdf",440674,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What is the main focus of this comprehensive review?\",\"answer\":\"The review evaluates synergistic effects between anticoagulants and platelet aggregation inhibitors when combined with immune checkpoint inhibitors in cancer therapy, based on both preclinical and clinical evidence.\"},{\"question\":\"What do preclinical studies suggest about combining ICIs with anticoagulants?\",\"answer\":\"Preclinical studies consistently indicate improved antitumor activity, including inhibition of tumor growth and metastasis, with agents such as low molecular weight heparin and oral Factor Xa inhibitors.\"},{\"question\":\"How do clinical findings compare, and what future research is recommended?\",\"answer\":\"Clinical results are mixed, though some retrospective evidence suggests potential benefit with Factor Xa inhibitors and antiplatelet agents; the study recommends prospective randomized trials to clarify interactions and outcomes.\"}]","Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy - a comprehensive review of preclinical and clinical evidence | PDF",1790061269,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63cb7411df5198a086017a9e21fb0324.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5e22cc29779cae2f0c7baa0bfe81664.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0119f968ddf6a9e7ffa62ef21b3400b4.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12606e32555c0cc6207dd9ca6a403b61.webp",980,1306]